Windlas Biotech's new GMP-certified injectable facility expands manufacturing capabilities for global pharmaceutical markets.

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical company specializing in pharmaceutical-grade cannabis manufacturing is pleased to announce ...

Under the executed agreements, HYTN will utilize EU Good Manufacturing Practice (EU GMP) to process both bulk and finished ...

To support compliance, the government revised Schedule M of the Drugs and Cosmetics Rules, 1945, in 2023, outlining phased ...

India extended the deadline for small- and medium-sized pharmaceutical companies to comply with revised GMP compliance under ...

Windlas Biotech added 1.76% to Rs 1,033.15 after the company announced that its new state-of-the-art injectable facility has received Good Manufacturing Practices (GMP) certification.

(Image/Freepik) With the revised Schedule M guidelines for good manufacturing practices (GMP) to come into force from January 2025, and there’s no likely extension of the deadline for meeting ...

The proposed extension for drugmakers in adopting Schedule M of Drugs and Cosmetics Act and Rules comes mainly at the behest ...

Indian medical device manufacturers are enhancing GMP compliance and embracing proactive strategies to meet rising USFDA ...

Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority ...